• 1
    Creutzig U,Zimmermann M,Reinhardt D,Dworzak M,Stary J,Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004; 22: 4384-4393.
  • 2
    Lehrnbecher T,Varwig D,Kaiser J,Reinhardt D,Klingebiel T,Creutzig U. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004; 18: 72-77.
  • 3
    Riley LC,Hann IM,Wheatley K,Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol. 1999; 106: 436-444.
  • 4
    Sung L,Lange BJ,Gerbing RB,Alonzo TA,Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007; 110: 3532-3539.
  • 5
    Lange BJ,Smith FO,Feusner J, et al. Outcomes in CCG-2961, a Children's Cancer Group phase 3 trial for untreated pediatric acute myeloid leukemia (AML). Blood. 2007; 111: 1044-1053.
  • 6
    Woods WG,Kobrinsky N,Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996; 87: 4979-4989.
  • 7
    Woods WG,Neudorf S,Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001; 97: 56-62.
  • 8
    Alonzo TA,Kobrinsky NL,Aledo A,Lange BJ,Buxton AB,Woods WG. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. J Pediatr Hematol Oncol. 2002; 24: 627-635.
  • 9
    Ascioglu S,Rex JH,de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34: 7-14.
  • 10
    Gamis AS,Howells WB,DeSwarte-Wallace J,Feusner JH,Buckley JD,Woods WG. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891. J Clin Oncol. 2000; 18: 1845-1855.
  • 11
    Gafter-Gvili A,Fraser A,Paul M,Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005; 142(12 pt 1): 979-995.
  • 12
    Engels EA,Lau J,Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998; 16: 1179-1187.
  • 13
    Dekker A,Bulley S,Beyene J,Dupuis LL,Doyle JJ,Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006; 24: 5207-5215.
  • 14
    Lange BJ,Gerbing RB,Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005; 293: 203-211.